Journal
ONCOLOGY RESEARCH AND TREATMENT
Volume 37, Issue 3, Pages 128-134Publisher
KARGER
DOI: 10.1159/000358890
Keywords
Pancreatic cancer; Chemotherapy; Nab-paclitaxel; Stroma; SPARC
Categories
Funding
- Celgene Corporation
Ask authors/readers for more resources
For almost 15 years there has been stagnation in the -systemic treatment of patients with pancreatic ductal -adenocarcinoma (PDAC). Recently, several developments seem to indicate clinically relevant improvements in the treatment of patients with metastatic disease. One of these developments is the introduction of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) into the first-line treatment of metastatic disease. In this review, underlying preclinical and clinical data are discussed, with a special focus on mechanisms of action, the potential interaction with albumin and calcium-binding matricellular glycoproteins, such as the secreted protein acidic and rich in cysteine (SPARC), as well as the clinical outcome associated with the use of nab-paclitaxel.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available